Bank of New York Mellon Corp lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 25.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 464,191 shares of the biotechnology company’s stock after purchasing an additional 94,160 shares during the period. Bank of New York Mellon Corp owned 0.47% of BioCryst Pharmaceuticals worth $2,279,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of BCRX. The Manufacturers Life Insurance Company grew its position in BioCryst Pharmaceuticals by 21.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 76,741 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 13,760 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $155,000. Alps Advisors Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 37.7% during the 4th quarter. Alps Advisors Inc. now owns 109,044 shares of the biotechnology company’s stock valued at $535,000 after buying an additional 29,841 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 55.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 496,792 shares of the biotechnology company’s stock valued at $2,440,000 after buying an additional 176,714 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $23,762,000. Institutional investors own 91.45% of the company’s stock.
BioCryst Pharmaceuticals stock opened at $5.01 on Monday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $3.95 and a twelve month high of $7.39. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.68 and a current ratio of 1.68. The stock has a market capitalization of $504.37, a PE ratio of -6.42 and a beta of 2.71.
BCRX has been the topic of a number of analyst reports. Barclays initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. ValuEngine cut shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 14th. Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Tuesday, January 2nd. Finally, Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $8.29.
WARNING: “Bank of New York Mellon Corp Has $2.28 Million Stake in BioCryst Pharmaceuticals, Inc. (BCRX)” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/04/16/bank-of-new-york-mellon-corp-has-2-28-million-stake-in-biocryst-pharmaceuticals-inc-bcrx.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.